Leukemia News and Research

RSS
Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.
S*BIO begins SB1317 Phase 1 clinical trial in patients with advanced/refractory hematologic malignancies

S*BIO begins SB1317 Phase 1 clinical trial in patients with advanced/refractory hematologic malignancies

Researchers reconstitute first step of break repair in cancerous cells

Researchers reconstitute first step of break repair in cancerous cells

Lotsa Helping Hands' new feature connects community members to healthcare nonprofit organizations

Lotsa Helping Hands' new feature connects community members to healthcare nonprofit organizations

Dollar General joins St. Jude Children's Hospital for Thanks and Giving campaign

Dollar General joins St. Jude Children's Hospital for Thanks and Giving campaign

Cyclacel to present results of sapacitabine Phase 2 trial for MDS at ASH Meeting

Cyclacel to present results of sapacitabine Phase 2 trial for MDS at ASH Meeting

Personalised medicine could help develop effective treatments for serious diseases

Personalised medicine could help develop effective treatments for serious diseases

MK-4827 drug candidate shows promising anti-tumour activity in first human trial

MK-4827 drug candidate shows promising anti-tumour activity in first human trial

UC Berkeley receives $16.5 million to support three research centers to examine children's health

UC Berkeley receives $16.5 million to support three research centers to examine children's health

Merck announces FDA Advisory Committee approval of GARDASIL for anal cancer and AIN treatment

Merck announces FDA Advisory Committee approval of GARDASIL for anal cancer and AIN treatment

Targeted therapies could treat a broad range of cancers: Research

Targeted therapies could treat a broad range of cancers: Research

MedImmune to present data on oncology portfolio at two medical congresses in Europe and the U.S.

MedImmune to present data on oncology portfolio at two medical congresses in Europe and the U.S.

New OncoMap technique can detect point mutation in ovarian cancer

New OncoMap technique can detect point mutation in ovarian cancer

MLL purchases Access Array, EP1 Systems for high-throughput deep-resequencing analysis

MLL purchases Access Array, EP1 Systems for high-throughput deep-resequencing analysis

Diffusion Tensor Imaging MRI technique helps produce satisfactory images of nerve bundles

Diffusion Tensor Imaging MRI technique helps produce satisfactory images of nerve bundles

Hana Biosciences announces financial results of third quarter 2010

Hana Biosciences announces financial results of third quarter 2010

EntreMed reports $2.1 million net loss for third quarter 2010

EntreMed reports $2.1 million net loss for third quarter 2010

Study finds arsenic improves survival rate in APL patients

Study finds arsenic improves survival rate in APL patients

USPTO issues Notice of Allowance to Asuragen’s mir-205 for lung cancer diagnosis

USPTO issues Notice of Allowance to Asuragen’s mir-205 for lung cancer diagnosis

Cyclacel announces publication of sapacitabine in British Journal of Cancer

Cyclacel announces publication of sapacitabine in British Journal of Cancer

New discovery can develop diagnostic test to identify gene mutation in AML

New discovery can develop diagnostic test to identify gene mutation in AML

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.